BSX Jan 2025 57.500 call
| Previous close | 19.96 |
| Open | 19.96 |
| Bid | 19.70 |
| Ask | 21.10 |
| Strike | 57.50 |
| Expiry date | 2025-01-17 |
| Day's range | 19.96 - 19.96 |
| Contract range | N/A |
| Volume | |
| Open interest | 419 |
PR NewswireMODULAR ATP Study of the mCRM™ System Meets Primary Safety and Efficacy Endpoints
Boston Scientific Corporation (NYSE: BSX) today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM™ System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System and the EMPOWER™ Leadless Pacemaker (LP). As components of the mCRM System, the devices are designed to work together wirelessly to coordinate painless intracardiac anti-tachycardia pacing (ATP) therap
ZacksVeeva's (VEEV) Vault Basics to Boost Efficiency for Biotechs
Veeva (VEEV) announces the availability of Vault Basics for biotechs, which aims to deliver complete and pre-validated solutions for expanding businesses.
ZacksAxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft
AxoGen (AXGN) starts the process of BLA submission to the FDA for the approval of its Avance Nerve Graft.
